Adalimumab serum levels and antidrug antibodies towards adalimumab in peripheral spondyloarthritis: no association with clinical response to treatment or with disease relapse upon...

por Paramarta, Jacqueline E, Baeten, Dominique L
Publicado 2014

Synovial Tissue Response to Treatment with TNF Blockers in Peripheral Spondyloarthritis

por Paramarta, Jacqueline E, Baeten, Dominique, De Rycke, Leen
Publicado 2011

Calprotectin (S100A8/9) as serum biomarker for clinical response in proof-of-concept trials in axial and peripheral spondyloarthritis

por Turina, Maureen C, Yeremenko, Nataliya, Paramarta, Jacqueline E, De Rycke, Leen, Baeten, Dominique
Publicado 2014

A proof-of-concept study with the tyrosine kinase inhibitor nilotinib in spondyloarthritis

por Paramarta, Jacqueline E., Turina, Maureen C., Noordenbos, Troy, Heijda, Tanja F., Blijdorp, Iris C., Yeremenko, Nataliya, Baeten, Dominique
Publicado 2016

Peripheral disease contributes significantly to the level of disease activity in axial spondyloarthritis

por de Winter, Janneke J, Paramarta, Jacqueline E, de Jong, Henriëtte M, van de Sande, Marleen G, Baeten, Dominique L
Publicado 2019

A psychometric analysis of outcome measures in peripheral spondyloarthritis

por Turina, Maureen C, Ramiro, Sofia, Baeten, Dominique L, Mease, Philip, Paramarta, Jacqueline E, Song, In-Ho, Pangan, Aileen L, Landewé, Robert
Publicado 2016